News & Updates
Filter by Specialty:
Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery
Apixaban is not inferior to enoxaparin for extended-duration venous thromboembolic event (VTE) prophylaxis (EP) following urologic oncology surgery, reveals a study. In addition, apixaban is associated with fewer major complications and compliance-related adverse events.
Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery
29 Sep 2022
Adjuvant pembrolizumab continues to improve DFS in clear cell RCC
In patients with clear cell renal cell carcinoma (RCC), adjuvant pembrolizumab continues to improve disease-free survival (DFS) over placebo, according to extended follow-up of the phase III KEYNOTE-564 trial.
Adjuvant pembrolizumab continues to improve DFS in clear cell RCC
28 Sep 2022
FINLAY-FR-1A vaccine boosts natural immunity in COVID-19 convalescents
A single dose of FINLAY-FR-1A, a recombinant d-RBD*-based COVID-19 vaccine, strengthens pre-existing natural immunity in patients who have recovered from asymptomatic, mild or moderate COVID-19, and has an excellent safety profile, a phase IIa/b study has shown.
FINLAY-FR-1A vaccine boosts natural immunity in COVID-19 convalescents
28 Sep 2022
First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer
Among older patients with metastatic breast cancer, first-line treatment with reduced-dose eribulin mesylate is reasonably safe but yields a low disease control rate, reports a recent phase II trial.
First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer
27 Sep 2022
Add-on reslizumab cuts exacerbations, OCS use in severe eosinophilic asthma
Reslizumab, a biologic targeting interleukin(IL)-5, reduced severe asthma exacerbation rate and oral corticosteroid (OCS) use in individuals with severe eosinophilic asthma, according to a real-world study using patient-level data from RAPSODI*.